Product Information
- (+)-Larixol
- (αS,1S,4S,4aS,8aR)-α-Ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-1-naphthalenepropanol
- 1-Naphthalenepropanol, alpha-ethenyldecahydro-4-hydroxy-alpha,5,5,8a-tetramethyl-2-methylene-, [1S-[1alpha(R),4beta,4abeta,8aalpha]]-
- 1-Naphthalenepropanol, α-ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-, (αS,1S,4S,4aS,8aR)-
- 1-Naphthalenepropanol, α-ethenyldecahydro-4-hydroxy-α,5,5,8a-tetramethyl-2-methylene-, [1S-[1α(R*),4β,4aβ,8aα]]-
- 4-(3-Hydroxy-3-methyl-4-pentenyl)-4a,8,8-trimethyl-3-methylenedecahydro-1-naphthalenol
- Labda-8(20),14-diene-6alpha,13-diol, (13S)-
- Labda-8(20),14-diene-6α,13-diol, (13S)-
- [(1S,4S,4aR,8aS)-4-[(3S)-3-acetoxy-3-methyl-pent-4-enyl]-4a,8,8-trimethyl-3-methylene-decalin-1-yl] acetate
Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical for immune responses. It disrupts the interaction between the βγ subunit of the Gi protein and downstream effectors linked to the fMLP receptor, thus abrogating fMLP-induced respiratory bursts. Additionally, larixol effectively reduces fMLP (0.1 μM)-triggered superoxide anion generation (IC50: 1.98 μM), cathepsin G secretion (IC50: 2.76 μM), and cellular chemotaxis, mitigating neutrophil hyperactivation and subsequent inflammation or tissue injury. Derivatives of larixol also demonstrate inhibitory activity on TRPC6 functional mutants associated with FSGS [1] [2].
Chemical properties
Technical inquiry about: TM-T80653 Larixol
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
